Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry

Modern Pathology

Volumn 14, Issue 7, 2001, Pages 686-694

  Natkunam, Yasodha ^a   Warnke, Roger A ^a   Montgomery, Kelli ^a   Falini, Brunangelo ^b   Van De Rijn, Matthijs ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

CD138; Immunohistochemistry; IRF4; Lymphoma; Melanoma; Multiple myeloma; MUM 1; Plasma cell; Tissue microarray; VS38

Indexed keywords

INTERFERON REGULATORY FACTOR 4; PARAFFIN; PROTEIN MUM1; PROTEIN VS38; SYNDECAN; SYNDECAN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 6; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS;

EID: 0034922730     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880373     Document Type: Article

References (48)

1. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
2. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia
3. Multiple myeloma: Increasing evidence for a multistep transformation process
4. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator
5. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon- stimulated response element (ISRE)
6. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function
7. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes
8. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25
9. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
10. Transcription factors in lymphocyte development-T and B cells get together
11. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1
12. A two-step mechanism for recruitment of Pip by PU.1
13. Cooperative interaction between the DNA-binding domains of PU.1 and IRF4
14. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies
15. A monoclonal antibody (MUMlp) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells
16. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
17. Cell surface heparan sulfate proteoglycan and the neoplastic phenotype
18. Hierarchical organization of hematopoietic microenvironments: Role of proteoglycans
19. Proteoglycans: Structures and interactions
20. Syndecans: Multifunctional cell-surface interacreceptors
21. Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryo
22. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
23. B lymphocytes express and lose syndecan at specific stages of differentiation
24. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia
25. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas
26. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1
27. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease
28. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas
29. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
30. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation
31. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein
32. A panel of antibodies for the immunostaining of Bouin's fixed bone marrow trephine biopsies
33. VS38: A new monoclonal antibody for detecting plasma cell differentiation in routine sections
34. Expression of VS38 in osteoblasts and stroma cells of bone tumors
35. VS38 immunostaining in melanocytic lesions
36. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes
37. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells
38. Specificity of plasma cell antibody VS38
39. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
40. Tissue microarrays for high-throughput molecular profiling of tumor specimens
41. Follicular large-cell lymphoma: Intermediate or low grade?
42. Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars
43. Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems
44. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes)
45. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease
46. BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major
47. The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation
48. BCL-6 protein is expressed in germinal-center B cells